Related references
Note: Only part of the references are listed.
Review
Oncology
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
A. Pardanani
LEUKEMIA (2008)
Article
Oncology
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
A. Pardanani et al.
LEUKEMIA (2007)
Article
Hematology
Concurrent MPL515 and JAK2V617F mutations in myelofibrosis:: chronology of clonal emergence and changes in mutant allele burden over time
Terra L. Lasho et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)